Projects per year
Our group investigates the primary brain tumour glioblastoma (GBM), one of the most aggressive and incurable tumours in adults. Treatment comprises surgery, radiation, and chemotherapy (temozolomide). Even with this aggressive therapy, tumours inevitably recur, conferring a life expectancy of approximately one year. Intensive research using conventional preclinical models, such as cells are grown in two-dimensional conditions (plastic dishes) or in three-dimensional models devoid of extracellular matrix or scaffolding support such as neurospheres, have identified multiple molecular targeted agents which have all failed in the clinic. Failure in the clinical translation of these agents imply that the conventional preclinical models used are not representative of GBM or its response to treatment. To elicit improved therapies for GBM patients and improve the poor survival rates, research in our group has focused in the development of appropriate models that better recapitulate the GBM microenvironment and evaluate how these cells respond to treatment.
Using a three-dimensional GBM model developed in our laboratory, that recapitulates key clinical features including cell morphology, migration, and clinical response to molecular targeted therapies, we have identified several molecular targets that induce radiation sensitivity as well as radiation protection. We are currently investigating the mechanisms involved in these responses, in order to identify better treatments with clinical efficacy.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
- ovarian cancer
- DNA damage and repair
Dive into details
Select a country/territory to view shared publications and projects
Understanding the role of cholesterol in the survival and treatment resistance of glioblastoma and its feasibility as a druggable target
Gomez-Roman, N. & Morgan, J.
1/10/21 → 30/09/24
Project: Research Studentship - Internally Allocated
Developing more representative laboratory models of the blood-tumour barrier to improve the drug development pipeline for patients with glioblastoma.
Chalmers, A., Carruthers, R. D., Birch, J., Smith, C., Ireson, C., Brennan, P., Thompson, G., Gomez-Roman, N., Salmeron-Sanchez, M. & Brunton, V.
1/09/21 → 31/08/24
Abstract PO-017: radiotherapy in combination with the brain penetrant ATM inhibitor AZD1390 does not exacerbate radiation toxicity of neural stem cells in vitro or in vivoGuttierez-Quintana, R., Walker, D. J., Jackson, M. R., Gomez-Roman, N., Chahal, S., Durant, S. T. & Chalmers, A. J., 15 Apr 2021, In: Clinical Cancer Research. 27, 8_Supplement, 1 p., PO-017.
Research output: Contribution to journal › Meeting abstract › peer-reviewOpen AccessFile1 Downloads (Pure)
Koessinger, A. L., Koessinger, D., Stevenson, K., Cloix, C., Mitchell, L., Nixon, C., Gomez-Roman, N., Chalmers, A. J., Norman, J. C. & Tait, S. W. G., 21 Sep 2020, In: Scientific Reports. 10, 1, 10 p., 15361.
Research output: Contribution to journal › Article › peer-reviewOpen AccessFile8 Downloads (Pure)